March 15, 2024 07:00 AM EDTUpdated 03:10 PM

Biogen loses CMO, neuromuscular leader; John Hood adds president, CFO at Endeavor BioMedicines

Alex Hoffman

Senior Editor

Kathy Wong

Editor

→ Biogen chief medical officer Maha Radhakrishnan is out after four years “as of March 1,” a spokesperson tells Peer Review. Biogen didn’t draw up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen loses CMO, neuromuscular leader; John Hood adds president, CFO at Endeavor BioMedicines

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Bio­gen los­es CMO, neu­ro­mus­cu­lar leader; John Hood adds pres­i­dent, CFO at En­deav­or Bio­Med­i­cines

Senior Editor

Editor

Sign up to read this article for free.

Biogen loses CMO, neuromuscular leader; John Hood adds president, CFO at Endeavor BioMedicines